Meta-analysis: Beyond the grand mean?

BMJ

Volumn 315, Issue 7122, 1997, Pages 1610-1614

  Smith, George Davey ^a   Egger, Matthias ^a   Phillips, Andrew N ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL PRACTICE; CLINICAL TRIAL; HEART INFARCTION; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; SHORT SURVEY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

CONFOUNDING FACTORS (EPIDEMIOLOGY); META-ANALYSIS; REGRESSION ANALYSIS; RISK ASSESSMENT;

EID: 0041295664     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.315.7122.1610     Document Type: Article

References (37)

1. Egger M, Davey Smith G. Meta-analysis: potentials and promise. BMJ 1997; 315: 1371–4.
2. Egger M, Davey Smith G, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997; 315: 1533–7.
3. Wittes RE. Problems in the medical interpretation of overviews. Stat Med 1987; 6: 269–76.
4. The European Infarction Study Group. European infarction study (EIS). A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidiy and mortality. Eur Heart J 1984; 5: 189–202.
5. Efron B, Morris C. Stein's paradox in statistics. Sci Am 1977; 236: 119–27.
6. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992; 116: 78–84.
7. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266: 93–8.
8. Beta-Blocker Pooling Project Research Group. The beta-blocker pooling project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988; 9: 8–16.
9. Peto R. Statistical aspects of cancer trials. In: Halnan KE, ed. Treatment of cancer. London: Chapman and Hall, 1982.
10. Buyse ME. Analysis of clinical trial outcomes: some comments on subgroup analyses. Controlled Clinical Trials 1989; 10: 187–94S.
11. Mauri F, Gasparini M, Barbonaglia L, Santoro E, Franzosi M, Tognoni G, et al. Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated by streptokinase (the GISSI trial). Am J Cardiol 1989; 63: 1291–5.
12. Peto R. Misleading subgroup analysis in GISSI. Am J Cardiol 1990; 64: 771
13. Schroeder R. Oxprenolol in myocardial infarction survivors: brief review of the European infarction study results in the light of other beta-blocker post infarction trials. Z Kardiol 1985; 74(suppl 6):165–72.
14. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progr Cardiovasc Dis 1985; 17: 335–71.
15. Peto R. Why do we need systematic overviews of randomized trials? Stat Med 1987; 6: 233–40.
16. Boissel JP, Leizorovicz A, Picolet H, Peyrieux JC. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol 1990; 66: 251–60.
17. Lopressor Intervention Trial Research Group. The lopressor intervention trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Eur Heart J 1987; 8: 1056–64.
18. Davey Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993; 306: 1367–73.
19. Bailey KR. Generalizing the results of randomized clinical trials. Controlled Clinical Trials 1994; 15: 15–23.
20. Holme I. Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol lowering trials. Controlled Clinical Trials 1996; 17: 13–22.
21. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311–22.
22. Zelen M. Intravenous streptokinase for acute myocardial infarction. New Engl J Med 1983; 308: 593.
23. Davey Smith G, Egger M. Meta-analysis: unresolved issues and future developments. BMJ (in press).
24. Davey Smith G. Low blood cholesterol and non-atherosclerotic disease mortality: where do we stand? Eur Heart J 1997; 18: 6–9.
25. Davey Smith G, Egger M. Who benefits from medical interventions? Treating low risk patients can be a high risk strategy. BMJ 1994; 308: 72–4.
26. Antiplatelet Trialist's Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.
27. Fischl MA, Richman DD, Griego MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185–91.
28. Egger M, Neaton JD, Phillips AN, Davey Smith G. Concorde trial of immediate versus deferred zidovudine. Lancet 1994; 343: 1355.
29. Egger M, Davey Smith G. Risks and benefits of treating mild hypertension: a misleading meta-analysis? J Hypertens 1995; 13: 813–5.
30. Sharp SJ, Thompson SG, Altman DG. The relation between treatment benefit and underlying risk in meta-analysis. BMJ 1996; 313: 735–8.
31. Thompson SG, Smith TEC, Sharp SJ. Investigating underlying risk as a source of heterogeneity and meta-analysis. Stat Med (in press).
32. Hoes AW, Grobbee DE, Lubsen J. Does drug treatment improve survival? Reconciling the trials in mild-to-moderate hypertension. J Hypertens 1995; 13: 805–11.
33. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987; 107: 224–33.
34. McIntosh MW. The population risk as an explanatory variable in research synthesis of clinical trials. Stat Med 1996; 15: 1713–28.
35. Garg R, Yusuf S for the Collaborative Group on ACE Inhibitor Trials. Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–6.
36. Phillips AN, Davey Smith G. How independent are “independent” effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 1991; 44: 1223–31.
37. Davey Smith G, Phillips AN. Confounding in epidemiological studies: why “independent” effects may not be all they seem. BMJ 1992; 305: 757–9.